Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2176 to 2190 of 7682 results

  1. Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers (MTG20)

    Evidence-based recommendations on Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers.

    Medical technologies guidance
    Last updated
    19 May 2021
    View recommendations

    Sections for MTG20

  2. Pipeline Flex embolisation device with Shield Technology for the treatment of complex intracranial aneurysms (MTG10)

    Evidence-based recommendations on the Pipeline Flex embolisation device with Shield Technology for the treatment of complex intracranial aneurysms.

    Medical technologies guidance
    Last updated
    9 January 2019
    View recommendations

    Sections for MTG10

  3. Durvalumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6168]

    Awaiting development [GID-TA11115] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]

    Awaiting development [GID-TA11365] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]

    In development [GID-TA11215] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Memokath 051 Ureter stent for ureteric obstruction (MTG75)

    Evidence-based recommendations on Memokath 051 Ureter stent for ureteric obstruction.

    Medical technologies guidance
    Published
    7 December 2022
    View recommendations

    Sections for MTG75

  7. AposHealth for knee osteoarthritis (MTG76)

    Evidence-based recommendations on AposHealth for knee osteoarthritis.

    Medical technologies guidance
    Published
    11 April 2023
    View recommendations

    Sections for MTG76

  8. Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer (MTG72)

    Evidence-based recommendations on Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer.

    Medical technologies guidance
    Published
    5 October 2022
    View recommendations

    Sections for MTG72

  9. The Sherlock 3CG Tip Confirmation System for placement of peripherally inserted central catheters (MTG24)

    Evidence-based recommendations on The Sherlock 3CG Tip Confirmation System for placement of peripherally inserted central catheters.

    Medical technologies guidance
    Last updated
    30 May 2019
    View recommendations

    Sections for MTG24

  10. Mega Soft Patient Return Electrode for use during monopolar electrosurgery (MTG11)

    Evidence-based recommendations on Mega Soft Patient Return Electrode for use during monopolar electrosurgery.

    Medical technologies guidance
    Published
    22 August 2012
    View recommendations

    Sections for MTG11

  11. Ambu aScope4 Broncho for use in unexpected difficult airways (MTG14)

    Evidence-based recommendations on Ambu aScope4 Broncho for use in unexpected difficult airways.

    Medical technologies guidance
    Last updated
    17 June 2019
    View recommendations

    Sections for MTG14

  12. iFuse for treating chronic sacroiliac joint pain (MTG39)

    Evidence-based recommendations on iFuse for treating chronic sacroiliac joint pain.

    Medical technologies guidance
    Last updated
    30 August 2022
    View recommendations

    Sections for MTG39

  13. Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care (DG56)

    Evidence-based recommendations on quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care

    Diagnostics guidance
    Published
    24 August 2023
    View recommendations

    Sections for DG56

  14. Freelite assays for diagnosing multiple myeloma and related conditions (terminated assessment) (DG47)

    NICE no longer plans to develop guidance on Freelite assays for diagnosing multiple myeloma and related conditions in primary care. We will review this decision if a stakeholder notifies NICE again of the topic

    Diagnostics guidance
    Published
    30 March 2022

    Sections for DG47

  15. MRI-based technologies for assessing non-alcoholic fatty liver disease (DG50)

    Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease

    Diagnostics guidance
    Published
    12 January 2023
    View recommendations

    Sections for DG50